title: Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients.
abstract: Warfarin therapy is used in lupus anticoagulant patients with thrombosis and yet the prothrombin time (PT)/international normalized ratio (INR) in these patients can sometimes be falsely elevated. Both a PT-based factor II (FII) assay and a chromogenic, enzymatic factor X (CFX) assay have been used for monitoring when the INR may be artifactual. This study compared FII and CFX assays in lupus anticoagulant-positive and lupus anticoagulant-negative warfarin-treated patients in a cross-sectional study of samples from 21 lupus anticoagulant-positive and 19 lupus anticoagulant-negative outpatients. Plasma samples were simultaneously measured for FII and CFX and the ratio of FII/CFX was used to measure concordance. Compared with lupus anticoagulant-negative patients 14 of the 21 lupus anticoagulant-positive patients had lower FII/CFX ratios (P < 0.01). Three of the patients had ratios less than 0.6 indicating strong disagreement (P < 0.0001). The patient with the lowest FII/CFX ratio had evidence suggesting a specific antibody to FII. Another patient showed that the discordance between FII and CFX varied over time. The CFX assay in the laboratory was technically superior, more precise, and less costly. The CFX assay is preferred for warfarin therapy monitoring in lupus anticoagulant patients when INR artifacts are suspected.
authors.affiliation: Medical Education Department and Coagulation Laboratory, Abbott Northwestern Hospital, Minneapolis, Minnesota 55407, USA.
authors.forename: Terry K
authors.initials: TK
authors.lastname: Rosborough
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Jacobsen
authors.forename: Michele F
authors.initials: MF
authors.lastname: Shepherd
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005170:Factor X / Q000378:metabolism*; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000627:therapeutic use*; D011516:Prothrombin / Q000378:metabolism*; D013927:Thrombosis / Q000188:drug therapy*; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D016682:Lupus Coagulation Inhibitor; D014859:Warfarin; D011516:Prothrombin; D005170:Factor X